Mereo BioPharma Group Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Mereo BioPharma Group plc (MREO) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-43.25-29.47-35.1314.24-223.40-41.12-37.31
Depreciation & Amortization1.091.060.890.642.181.580.00
Stock Based Compensation7.394.924.774.462.130.000.00
Change in Working Capital-0.37-1.59-2.35-1.85-4.66-7.672.41
Change in Accounts Receivable-1.650.000.00-0.800.190.000.00
Change in Accounts Payable0.15-1.260.62-1.70-4.850.000.00
Change in Other Working Capital-0.52-0.332.1018.100.000.000.00
Other Operating Activities2.313.942.103.95170.260.902.34
Net Cash from Operating Activities-32.83-21.13-48.82-5.24-38.69-45.93-23.14
Investing Activities
Capital Expenditures-0.700.34-0.010.54-0.020.020.04
Acquisitions0.000.000.000.00-0.4810.070.00
Sales/Maturities of Investments-0.70-0.422.000.152.4932.870.00
Other Investing Activities-0.701.630.020.000.060.000.00
Net Cash from Investing Activities-0.70-0.421.99-0.422.0443.300.25
Financing Activities
Debt Repayment0.00-3.18-1.13-0.690.00-2.210.00
Common Stock Issued47.0011.610.0078.5327.49-1.000.27
Other Financing Activities-0.85-0.440.20-0.23-10.77-0.760.08
Net Cash from Financing Activities46.157.970.2077.6547.43-5.71-2.08
Summary
Effect of Forex Changes on Cash-0.230.02-12.58-1.170.00-0.35-0.04
Net Change in Cash12.38-10.76-46.6370.839.72-8.70-25.00
Cash at Beginning of Period57.4256.33127.4023.470.0025.0450.05
Cash at End of Period69.8045.1068.1894.300.0016.3525.04
Free Cash Flow-32.83-21.13-48.83-5.24-38.720.00-23.14
Supplemental Disclosures
Interest Paid0.020.880.020.003.960.000.00
Income Taxes Paid0.00-1.341.880.000.000.000.00